来稿:陈琳  北京康复中心神经外科

Exp Ther Med. 2013  Jul;6(1):140-146.

 

A clinical trial report of autologous bone marrow-derived  mesenchymal stem cell transplantation in patients with spinal cord  injury

 

Wu DC.

 

Spinal cord injury (SCI) is a severe neurological  disease. An effective strategy for the treatment of SCI is urgently required.  Stem cell transplantation has emerged as a viable therapeutic option with great  potential for restoring neurological function lost following SCI. From 2009 to  2010, a total of 20 SCI patients were enrolled in a clinical trial by Wuhan Hongqiao Brain Hospital; all patients completed and  signed informed consent prior to autologous bone marrow-derived mesenchymal stem  cell transplantation. Analysis of subsequent treatment results indicated  significant improvements in sensory, motor and autonomic nerve function as  assessed by the American Spinal Injury Association's impairment scale. Thirty  days after transplantation, a total of 15 patients (75%) demonstrated  improvement, including four of the eight patients (50%) with grade A SCI, three  of the four patients (75%) with grade B injury and all eight patients (100%)  with grade C injury. The most common adverse events, fever and headache,  disappeared within 24-48 h without treatment.


自体骨髓间充质干细胞移植治疗晚期完全性颈脊髓损伤
完全性脊髓损伤患者自体嗅鞘细胞移植

Previous:

Next:

脊髓损伤患者自体骨髓间充质干细胞移植临床研究报告